Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CATARACT SURGERY WAS APPROPRIATE IN UP TO 84% OF MEDICARE PATIENTS

This article was originally published in The Gray Sheet

Executive Summary

CATARACT SURGERY WAS APPROPRIATE IN UP TO 84% OF MEDICARE PATIENTS who underwent the procedure, according to the results of a patient survey conducted by the General Accounting Office at the request of Senate Aging Committee Chairman David Pryor (D-Ark.) and released on April 21. "About three-quarters of Medicare patients reported one or more substantial functional impairments affecting their ability to drive, read or watch television prior to their cataract surgery," GAO states, adding that "these responses generally support the appropriateness of the procedure for these patients." Furthermore, the report continues, "with the inclusion of symptoms such as blurred vision or sensitivity to glare, the proportion of patients with substantial presurgical vision problems increased to 84%." For the remaining 16%, GAO notes, "surgery may have been more questionable...depending on the weight given to 'slight' symptoms and functional limitations relative to the risks of the surgery." Cataract surgery is the largest single procedure reimbursed by Medicare. In 1991, the program paid $3.4 bil. for approximately 1.3 mil. surgeries. The expenditures accounted for roughly 3% of total Medicare outlays. The survey was intended to obtain patient assessments of their symptoms and functional impairments both before and after surgery. A total of 1,964 questionnaires were mailed to a random sample of Medicare beneficiaries in California, Massachusetts, Pennsylvania and Texas. GAO obtained usable responses from 1,488, or 76%. "With respect to the long-term outcomes of the surgery, the overwhelming majority of respondents reported that they improved on one or more symptoms and functional impairments," the report states. "For about two-thirds, this improvement was uniform across all dimensions (that is, the symptoms and functions that did not get better at least stayed unchanged). Most of the other patients reported mixed results, with improvements in some symptoms or functional impairments and worsening in others."

You may also be interested in...



Adalvo Hails First European Launch Of Prolonged-Release Pregabalin

After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.

Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results

Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000525

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel